San Jose, CA -- Wednesday, August 12, 2009 -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the launch of the BD™ Kaleidoscope reagent and dye expansion program – marked by the initial release of nearly 200 new fluorochrome-conjugated antibodies for flow cytometry to help meet today’s life science research needs.
“Multicolor flow cytometry empowers researchers who are conducting complex experiments to analyze multiple parameters simultaneously, enhancing discovery and problem solving by providing them with a wealth of information in a single experiment,” said Jay Glasscock, President, Cell Analysis, BD Biosciences. “These 200 new products from the BD Kaleidoscope program represent simply the beginning of our significant portfolio expansion designed to support the growing base of applications that can benefit from this powerful technology.”
The BD Kaleidoscope portfolio offers these new fluorochrome-conjugated antibodies in a full range of colors, making it easier to construct multicolor cocktails to obtain fluorescently separated cell populations more efficiently. In addition, researchers can choose from a wide range of sizes, such as the new 50 test/50 mg size to reduce the cost of initial panel design and testing. The new BD reagents, like others in the BD Biosciences portfolio, are optimized for use with BD flow cytometry systems.
Information about the BD Kaleidoscope reagent and dye expansion program can be found on the new and improved web site – www.bdbiosciences.com. Based on customer feedback, the new site provides more user-friendly navigation and searching capabilities. Other enhancements include the new BD Cell Pathways tool, powered by Ingenuity systems, which allows researchers to explore pathways, find relevant information and optimize experiments.
For more information about the BD Kaleidoscope reagent and dye expansion program and all of BD Biosciences’ offerings, please visit http://www.bdbiosciences.com/colors.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.
